Adjuvant Subcutaneous Trastuzumab for HER2-Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study.
Fiche publication
Date publication
juillet 2018
Journal
The oncologist
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier
Tous les auteurs :
Jung KH, Ataseven B, Verrill M, Pivot X, De Laurentiis M, Al-Sakaff N, Lauer S, Shing M, Gligorov J, Azim HA
Lien Pubmed
Résumé
This SafeHer subgroup analysis assessed the safety of fixed-dose subcutaneous trastuzumab (H SC) as an adjuvant therapy in HER2-positive early breast cancer (EBC) by body weight.
Mots clés
Asian population, Body weight, Breast cancer, Human epidermal growth factor receptor 2‐positive, Subcutaneous injections, Trastuzumab
Référence
Oncologist. 2018 Jul 17;: